10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-ERBB1 / EGFR / HER1 Reference Antibody (losatuxizumAb)

Recombinant Antibody
Catalog # APR10384

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P00533
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1-EM
Calculated MW	134277

Additional Information


Target/Specificity	ERBB1 / EGFR / HER1
Endotoxin	
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information


Name	EGFR {ECO:0000303|PubMed:32926474, ECO:0000312|HGNC:HGNC:3236}
Function	Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:10805725, PubMed:12297050, PubMed:12620237, PubMed:12873986, PubMed:15374980, PubMed:15590694, PubMed:17115032, PubMed:19560417, PubMed:21258366, PubMed:27153536, PubMed:2790960, PubMed:35538033, PubMed:9488479). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues (PubMed:10026169, PubMed:17349580, PubMed:18046415, PubMed:19560417, PubMed:19836242). The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades (PubMed:10026169, PubMed:17349580, PubMed:18046415, PubMed:19560417, PubMed:19836242). Activates at least

	4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Acts as a positive regulator of cGAS-STING signaling by mediating tyrosine phosphorylation of STING1, promoting production of type I interferon (IFN-alpha and IFN-beta), while inhibiting STING1 ability to regulate autophagy (PubMed:32926474). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity).
Cellular Location	Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein Endosome Endosome membrane. Nucleus. Note=In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:17909029, PubMed:20674546). Endocytosed upon activation by ligand (PubMed:17182860, PubMed:17909029, PubMed:27153536, PubMed:2790960). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055)
Tissue Location	Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

Images



Anti-ERBB1 / EGFR / HER1 Reference Antibody (losatuxizumAb) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-ERBB1 / EGFR / HER1 Reference Antibody (losatuxizumAb) is 99%, determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.